Cost-effectiveness of programmed death ligand-1 (PD-L1) blockade in first-line for metastatic gastric/gastroesophageal junction cancer
- PMID: 36137394
- DOI: 10.1016/j.ejca.2022.08.017
Cost-effectiveness of programmed death ligand-1 (PD-L1) blockade in first-line for metastatic gastric/gastroesophageal junction cancer
Keywords: Cost of drugs; First-line; Metastatic gastric/gastroesophageal junction cancer; Nivolumab; Pembrolizumab.
Conflict of interest statement
Conflict of interest statement The authors have no relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
